Recent Updates
Recently added Catalysts
GH Positive Sentiment

Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening

Tuesday, September 1, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Guardant Health, Inc. announced that its Shield blood test for colorectal cancer screening will be covered by Carelon Healthcare Services starting November 15. Carelon is a significant specialty benefits manager in the U.S., enhancing the test's accessibility across more than 14 states. This coverage marks an important step for colorectal cancer detection.

Market Sentiment Analysis

POSITIVE FACTORS

  • Guardant Health's Shield blood test gains coverage for CRC screening.
  • Carelon Healthcare Services is a major player in health insurance.
  • The policy update enhances accessibility for colorectal cancer screening.

Full Press Release Details

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in Carelon Healthcare Services clinical guidelines effective November 15. Carelon Healthcare Services is one of the largest specialty benefits managers in the country and subsidiary of one of the largest health insurance companies in the U.S spanning more than 14 states. The new policy update fr

Frequently Asked Questions

What is the Shield blood test?

The Shield blood test is a screening tool for colorectal cancer developed by Guardant Health.

When will Carelon cover the Shield test?

Carelon will cover the Shield blood test starting November 15.

Who is Carelon Healthcare Services?

Carelon Healthcare Services is a large specialty benefits manager in the U.S.

How does this coverage impact patients?

The coverage enhances accessibility for patients needing colorectal cancer screening.

ShareAdd on Google
Tags: GH Viatris Investor Conferences Healthcare Guardant Health Shield test colorectal cancer Carelon Health Services health insurance
Last updated: Sep 1, 2026

Biotech snapshot

Cash runway
$1053M liquidity · $19M/mo burn
~54 mo
Minimal dilution risk